Latest News Kiadis to Acquire CytoSen Therapeutics, Inc. Transaction Information

Accelerating Innovation in NK Cell Therapy

CytoSen Method
Arrow See how the CytoSen Method works
Play Video
CytoSen NK cells
Arrow Take a look at CytoSen NK cells in action
Play Video

Mission

CytoSen’s mission is to accelerate innovation in NK cell therapies to deliver effective and safe to patients with the most difficult cancers through an innovative patented nanoparticle approach that both stimulates and expands NK cells to enable the production of therapeutically effective dosages of high potency.

Learn More
Mission

The CytoSen Method™

At the intersection of nanotechnology and immunotherapy, CytoSen brings forth a new paradigm in immuno-oncology by combining a patented approach to derive biologically active plasma-derived nanoparticles with groundbreaking discoveries in the use of membrane-bound stimulants to produce adoptive NK cell therapies at high doses and with high cancer-killing properties.

Learn More
The CytoSen Method
Take a look at the CytoSen Method
Play Video

Therapeutics

CytoSen’s NK cell therapy harnesses the power of the immune system to treat cancer by augmenting the patient’s innate immunity to eliminate the cancer cells. CytoSen’s pipeline will bring innovative NK cell therapies to over 100,000 cancer patients each year across a range of cancer types.

Learn More
Therapeutics

CytoSen scientists are actively investigating and developing the nanoparticle platform to make ever potent and “smart” NK cells.

CytoSen’s Next Gen Immuno-Oncology Therapies Have Broad Cancer-Fighting Potential

Unlike many immuno-oncology therapies being investigated today, CytoSen’s unique, patented methods produce cellular immunotherapeutics that are scalable and cost effective. Without a requirement for genetic modification or manipulation, CytoSen’s NK cell therapy has the potential to treat a broad range of cancers.

Learn More

In the News

Kiadis to Acquire CytoSen Therapeutics, Inc.

April 17, 2019

Transaction creates leader in cell-based cancer immunotherapy, with complementary T-cell and Nk-cell platforms focused initially on hematopoietic stem cell transplants (HSCT) CytoSen’s lead Nk-cell therapy candidate, CSDTO02-NK,…

Learn More